Kosloski, M. P., Liu, W., Wang, H., Pugatch, D., Mensa, F. J., Gane, E., . . . Kort, J. (2019). Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment. European Journal of Clinical Pharmacology, 75(2), 217-227.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Kosloski, Matthew P., et al. "Pharmacokinetics and Safety of Glecaprevir and Pibrentasvir in HCV-negative Subjects with Hepatic Impairment."
European Journal of Clinical Pharmacology 75, no. 2 (2019): 217-227.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Kosloski, Matthew P., et al. "Pharmacokinetics and Safety of Glecaprevir and Pibrentasvir in HCV-negative Subjects with Hepatic Impairment."
European Journal of Clinical Pharmacology, vol. 75, no. 2, 2019, pp. 217-227.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.